No abstract

No abstract

The risk of residual tumor after transurethral resection of transitional cell carcinoma is significantly decreased by 5-aminolevulinic acid fluorescence endoscopy.

In a prospective randomized trial, 800 patients undergoing intravenous urography were pretreated with either intravenous prednisolone (group I), the H₁-antagonist clemastin (group II), a combination of clemastin and the H₁-antagonist cimetidine (group III) or 0.9% saline (group IV). There was an overall incidence of 18–19% side reactions, when subjective and objective symptoms were regarded together. There was no significant difference between the four groups in the total incidence. The same applies when considering subjective side effects including the symptom ‘heat sensation’ that occurred in 10–12% of all patients. However, when side effects excluding the symptom ‘heat sensation’ were regarded and the individual groups were compared, there was a significant difference in frequency between the control group (12%) and the combined H₁/H₂ group (6%). Prednisolone and clemastin did not produce a significant reduction of side effects. The combined application of histamine H₁- and H₂-antagonists might be useful in prophylaxis of radiographic contrast media-induced adverse reactions.

The risk of residual tumor after transurethral resection of transitional cell carcinoma is significantly decreased by 5-aminolevulinic acid fluorescence endoscopy.